Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:26 PM
Ignite Modification Date:
2025-12-24 @ 6:26 PM
NCT ID:
NCT00047268
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Morphologically confirmed primary myelodysplastic syndromes (MDS)
* Diagnosed between July 1, 1998 and June 30, 2002
* No prior aplastic anemia
* No prior congenital bone marrow failure syndrome, such as:
* Fanconi's anemia
* Kostmann syndrome
* Shwachman syndrome
* Dyskeratosis congenital
* Amegakaryocytic thrombocytopenia
* Diamond-Blackfan anemia
* No Down syndrome
* None of the following cytogenetic or molecular abnormalities:
* t(8;21)(q22;q22)
* t(15;17)(q22;q12)
* inv(16)(p13;q22)
* No typical clinical and cytogenetic features of acute myeloid leukemia FAB M7 (i.e., acute megakaryocytic leukemia) with fewer than 30% blasts in bone marrow or peripheral blood
PATIENT CHARACTERISTICS:
Age
* Under 19
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* See Disease Characteristics
Hepatic
* Not specified
Renal
* Not specified
Other
* No other concurrent illness that would preclude study
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* No prior chemotherapy for MDS
Endocrine therapy
* Not specified
Radiotherapy
* No prior radiotherapy for MDS
Surgery
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
18 Years
Study:
NCT00047268
Study Brief:
Protocol Section:
NCT00047268